BeiGene | Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

⟵ Back to Search Results

Ociperlimab with Tislelizumab and Chemotherapy in Participants with Untreated Metastatic Non-Small Cell Lung Cancer

Beigene Study ID

AdvanTIG-205

ClinicalTrials.gov ID

NCT05014815

EudraCT Number

2021-001075-17

China Drug Trials ID

CTR20212782

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents